Is Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Fuel Running High? Reports Show Less Sellers

June 18, 2018 - By Adrian Erickson

The stock of Apellis Pharmaceuticals Inc (NASDAQ:APLS) registered a decrease of 8.16% in short interest. APLS’s total short interest was 1.64M shares in June as published by FINRA. Its down 8.16% from 1.79M shares, reported previously. With 514,900 shares average volume, it will take short sellers 3 days to cover their APLS’s short positions. The short interest to Apellis Pharmaceuticals Inc’s float is 6.98%.

The stock increased 1.20% or $0.27 during the last trading session, reaching $22.7. About 73,290 shares traded. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.27 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: which released: “UPDATE: Cantor Fitzgerald Starts Apellis Pharmaceuticals (APLS) at Overweight” on May 23, 2018, also with their article: “Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference” published on May 31, 2018, published: “32 Stocks Moving In Monday’s Mid-Day Session” on May 21, 2018. More interesting news about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were released by: and their article: “44 Biggest Movers From Yesterday” published on May 22, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 24, 2018.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.